Trial Profile
Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs Enobosarm (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors GTx
- 22 Feb 2024 Status changed from completed to discontinued.
- 22 Feb 2024 Planned End Date changed from 1 Aug 2018 to 1 Feb 2018.
- 22 Feb 2024 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2018.